Takeda Pharmaceutical (TAK) plans 33,696 ADS NYSE sale after prior RSU sales
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited filed to permit the sale of 33,696 American Depositary Shares (ADSs) through Interactive Brokers LLC on 07/13/2026 on the NYSE. The proposed sale has an aggregate market value of $564,406.02.
Over the prior three months, 126,794 ADSs were sold on 07/01/2026, arising from Restricted Stock Unit Awards – Vested granted as compensation.
Positive
- None.
Negative
- None.
Filing Explained
The July 13 notice covers 126,794 ADSs tied to vested RSUs, but records a proposed holder sale—not a completed change to Takeda’s share structure.
The
The disclosed transaction basis is compensation from vested RSU awards, and no trading plan is disclosed in this filing.
The filing lists an aggregate value of
The notice does not establish whether the proposed ADS sale was completed; that status would require evidence beyond this filing.
Key Figures
Key Terms
Restricted Stock Unit Awards financial
compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.